Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 3/2016

01-03-2016 | Literatur kommentiert

Kardiale Toxizität von Trastuzumab in der adjuvanten Therapie von Mammakarzinompatientinnen

Ergebnisse der NCCTG-N9831-Studie

Author: Dr. med. David Krug

Published in: Strahlentherapie und Onkologie | Issue 3/2016

Login to get access

Auszug

Der monoklonale Antikörper Trastuzumab, der gegen den Wachstumsfaktorrezeptor HER2/neu gerichtet ist, wurde 2006 zur adjuvanten Therapie des HER2-positiven Mammakarzinoms in Europa zugelassen. Kardiotoxische Nebenwirkungen von Trastuzumab waren bereits in frühen Studien beschrieben worden, ohne dass deren Mechanismus hätte abschließend geklärt werden können. Die hier kommentierte NCCTG-N9831-Studie sollte eine Nutzen-Risiko-Abwägung der kardiotoxischen Effekte gegenüber den positiven Effekten ermöglichen. …
Literature
1.
Chen T, Xu T, Li Y et al (2011) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37:312–320CrossRefPubMed
2.
Bowles EJA, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293–1305PubMedCentralCrossRefPubMed
3.
Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222–4228PubMedCentralCrossRefPubMed
4.
Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 353:1673–1684CrossRefPubMed
5.
Advani PP, Ballman KV, Dockter TJ et al (2015) Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. JCO.2015.61.8413
6.
Romond EH, Jeong J-H, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792–3799PubMedCentralCrossRefPubMed
7.
Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25:3525–3533CrossRefPubMed
8.
Halyard MY, Pisansky TM, Dueck AC et al (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 27:2638–2644PubMedCentralCrossRefPubMed
9.
Caussa L, Kirova YM, Gault N et al (2011) The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. Eur J Cancer 47:65–73CrossRefPubMed
10.
Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. New Engl J Med 372:134–141PubMedCentralCrossRefPubMed
Metadata
Title
Kardiale Toxizität von Trastuzumab in der adjuvanten Therapie von Mammakarzinompatientinnen
Ergebnisse der NCCTG-N9831-Studie
Author
Dr. med. David Krug
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 3/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-015-0938-8

Other articles of this Issue 3/2016

Strahlentherapie und Onkologie 3/2016 Go to the issue

Original Article

Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children

Original Article

Temporal changes in tumor oxygenation and perfusion upon normo- and hyperbaric inspiratory hyperoxia

Erratum

Erratum to: Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin

Original Article

Primary glioblastoma multiforme tumors and recurrence

Original Article

Radiotherapy of spinal cord gliomas

Original Article

Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients